Vectus Biosystems

Vectus Biosystems Pre-Tax Margin

The Pre-Tax Profit Margin of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is -371.67 %. In the previous year, Pre-Tax Profit Margin was -298.51 % — a change of 24.51% (lower).

Pre-Tax Margin

-371.67 %

YoY

24.51%

Last updated:

Pre-Tax Profit Margin of Vectus Biosystems is 2025 -371.67 % . Pre-Tax Profit Margin of Vectus Biosystems was 2024 -298.51 % . It decreases by 24.51% lower compared to the previous year.

The Vectus Biosystems Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-219,836.95 AUD
Jan 1, 2019
-1.13 M AUD
Jan 1, 2020
-6,602.78 AUD
Jan 1, 2021
-2.67 M AUD
Jan 1, 2022
-407.19 AUD
Jan 1, 2023
-349.72 AUD
Jan 1, 2024
-298.51 AUD
Jan 1, 2025
-371.67 AUD
The Vectus Biosystems Pre-Tax Margin history
YEARPre-Tax MarginYoY
-371.67 %+24.51%
-298.51 %-14.64%
-349.72 %-14.11%
-407.19 %-99.98%
-2.67 M %+40,267.24%
-6,602.78 %-99.42%
-1.13 M %+416.13%
-219,836.95 %+2,150.87%
-9,766.76 %+85.19%
-5,274.03 %-93.59%
-82,332.23 %+48,353.04%
-169.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Pre-Tax Profit Margin of Vectus Biosystems is -371.67 % in 2025.

Pre-Tax Profit Margin of Vectus Biosystems changed from -298.51 % to -371.67 %, representing a 24.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Vectus Biosystems

All Key Metrics — Vectus Biosystems